Viracta Therapeutics to Present at Upcoming May Investor Conferences

Rhea-AI Summary

Viracta Therapeutics, a precision oncology company focused on virus-associated malignancies, will present at key investor conferences this May. The first is the RBC Capital Markets 2022 Global Healthcare Conference on May 18, 2022, at 9:00 a.m. EDT, followed by the H.C. Wainwright Global Investment Conference on May 24, 2022, at 11:30 a.m. EDT. Both presentations will feature a fireside chat format. Investors can access live webcasts on the Viracta website, available for 30 days post-event. Viracta's lead therapy, Nana-val, is in ongoing clinical trials targeting EBV-positive malignancies.

SAN DIEGO, May 11, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management will present and participate in one-on-one meetings at the following investor conferences in May:

RBC Capital Markets 2022 Global Healthcare Conference
Presentation Date:         May 18, 2022
Presentation Time:         9:00 a.m. EDT
Format:                           Fireside chat

H.C. Wainwright Global Investment Conference
Presentation Date:         May 24, 2022
Presentation Time:         11:30 a.m. EDT
Format:                           Fireside chat

A live webcast of each presentation will be available on the Investors section of the Viracta website under "Events and Webcasts" at https://viracta.investorroom.com/events-and-webcasts. The webcasts will be archived for 30 days.

About Viracta Therapeutics, Inc.

Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is currently being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV⁺) lymphoma (NAVAL-1), as well as a multinational Phase 1b/2 trial for the treatment of EBV⁺ recurrent or metastatic nasopharyngeal carcinoma and other EBV⁺ solid tumors. Viracta is also pursuing the application of its inducible synthetic lethality approach in other virus-related cancers.

For additional information please visit www.viracta.com.

Investor Relations Contact:
Ashleigh Barreto
Head of Investor Relations & Corporate Communications
Viracta Therapeutics, Inc.
abarreto@viracta.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/viracta-therapeutics-to-present-at-upcoming-may-investor-conferences-301545450.html

SOURCE Viracta Therapeutics, Inc.

FAQ

What conferences will Viracta present at in May 2022?

Viracta will present at the RBC Capital Markets Global Healthcare Conference on May 18 and the H.C. Wainwright Global Investment Conference on May 24, 2022.

What is the format of Viracta's presentations at the investor conferences?

Both presentations will be in a fireside chat format.

Where can I watch the presentations from Viracta?

Live webcasts of the presentations will be available on the Investors section of the Viracta website under 'Events and Webcasts'.

What is Nana-val, Viracta's lead product candidate?

Nana-val is an all-oral combination therapy of nanatinostat and valganciclovir, currently evaluated in clinical trials for EBV-positive cancers.

When will Viracta's presentation at the RBC Capital Markets conference take place?

The presentation will take place on May 18, 2022, at 9:00 a.m. EDT.